

The future of immunotherapy for NSCLC: Targeting the tumour microenvironment

Practice Aid from a touchEXPERT OPINIONS

For more information, visit www.touchrespiratory.com/cme-education/immunotherapy-for-non-small-cell-lung-cancer



The tumour microenvironment and immunotherapy

TOUCH RESPIRATORY® www.touchrespiratory.com/cme-education/

Immunotherapeutic strategies for NSCLC Cell-associated targets





Immunotherapeutic strategies for NSCLC Soluble targets



(TGF-β receptor 1 inhibitor)

• NCT03732274 (phase I/II)

• NCT04396535 (phase II)

• NCT03631706 (phase III)

(mAb against TGF- β)

• NCT02581787 (phase I/II)

• NCT03840902 (phase II)

• NCT03840915 (phase I/II)

Abbreviations

Ab, antibody; CD, cluster of differentiation; CI, confidence interval; CTLA-4, cytotoxic T lymphocyte antigen-4; HR, hazard ratio; hsCRP, high-sensitivity C reactive protein; IFN-γ, interferon gamma; IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; IL-1R, interleukin-1 receptor; IL-1R1, interleukin-1 receptor 1; IL-1RAP, interleukin-1 receptor accessory protein; LAG-3, lymphocyte-activation gene 3; mAb, monoclonal antibody; MHC, major histocompatibility complex; NSCLC, non-small cell lung carcinoma; OS overall survival; PD-1, programmed death-1; PD-L1, programmed death-ligand-1; TGF-β, transforming growth factor beta; TGF-βRII, transforming growth factor beta receptor II; Th, T helper cell; TIL, tumour-infiltrating lymphocyte; Treg, regulatory T cell.

References

- 1. Pio R, et al. *Front. Immunol.* 2019;10:774.
- 2. Zou W, et al. Sci Transl Med. 2016;8:328rv4.
- 3. Seidel JA, et al. Front Oncol. 2018;8:1–14.
- 4. Hellmann MD, et al. *N Engl J Med*. 2019;381:2020–3.
- 5. He Y, et al. *Cancer Sci.* 2016;107:1193–7.
- 6. Datar IJ, et al. *Clin Cancer Res.* 2019;25:4663–73.
- 7. Garon EB, et al. *JTO Clin Res Rep*. 2020;1:100001.
- 8. Ridker PM, et al. *Lancet*. 2017;390:1833–42.
- 9. Ganesh K, Massagué J. Immunity. 2018;48:626–8.
- 10. Mariathasan S, et al. *Nature*. 2018;554:544–48.

Clinical trials listed by their identifiers at: ClinicalTrials.gov (accessed 01 September 2020).

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions, potential contraindications, and review any relevant manufacturer product information or recommendations of other authorities, prior to consideration of procedures, medications, or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s). TouchRESPIRATORY cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions.